Sugammadex + Neostigmine + Glycopyrrolate
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Surgical Procedures, Elective
Conditions
Surgical Procedures, Elective
Trial Timeline
Dec 2, 2011 โ Nov 5, 2012
NCT ID
NCT01479764About Sugammadex + Neostigmine + Glycopyrrolate
Sugammadex + Neostigmine + Glycopyrrolate is a phase 3 stage product being developed by Merck for Surgical Procedures, Elective. The current trial status is completed. This product is registered under clinical trial identifier NCT01479764. Target conditions include Surgical Procedures, Elective.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02860507 | Approved | Completed |
| NCT01479764 | Phase 3 | Completed |
Competing Products
20 competing products in Surgical Procedures, Elective